Acadia Pharmaceuticals says USPTO allows trofinetide dosing patent application, extending U.S. protection to March 2041
Bitget2026/09/28 20:05- ACADIA Pharmaceuticals received a USPTO Notice of Allowance for a U.S. patent covering weight-banded dosing of trofinetide for Rett syndrome.
- Expected patent term, including six months of pediatric exclusivity, runs through March 28, 2041, extending protection by nearly five years.
- Trofinetide also has a U.S. method-of-use patent for Rett syndrome that expires in July 2036.
- Trofinetide is marketed in the U.S. as DAYBUE and DAYBUE STIX for adults and pediatric patients ages 2 and older.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Besent “Extinguishes Fire”: Rising US Treasury yields are a global phenomenon, dismisses concerns over AI bubble
U.S. Treasury Secretary Janet Yellen defended the rise in U.S. Treasury yields, stating that this increase is a global phenomenon rather than unique to the United States, and does not warrant excessive concern. She partially attributed inflationary pressures to higher oil prices caused by the Iran conflict, and expects the energy shock to subside as hostilities ease. Yellen refuted the notion of an AI bubble, arguing that investments by major tech companies are grounded in solid business logic.
Crypto prices
More
